Editorial: Spotlight on resistant and refractory migraine.
作者信息
Ornello Raffaele, Raffaelli Bianca
机构信息
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Department of Neurology, Headache Center, Charité Universitätsmedizin Berlin, Berlin, Germany.
出版信息
Front Neurol. 2023 Sep 27;14:1291439. doi: 10.3389/fneur.2023.1291439. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Spotlight on resistant and refractory migraine.社论：聚焦耐药性和难治性偏头痛。
Front Neurol. 2023 Sep 27;14:1291439. doi: 10.3389/fneur.2023.1291439. eCollection 2023.
2
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance.抗药性和难治性偏头痛的负担与态度：一项由欧洲头痛联盟认可、欧洲偏头痛与头痛联盟发起的调查
J Headache Pain. 2021 May 18;22(1):39. doi: 10.1186/s10194-021-01252-4.
3
Breaking the cycle: unraveling the diagnostic, pathophysiological and treatment challenges of refractory migraine.打破循环：揭示难治性偏头痛的诊断、病理生理及治疗挑战
Front Neurol. 2023 Sep 27;14:1263535. doi: 10.3389/fneur.2023.1263535. eCollection 2023.
4
Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the majority of cases.82 例突发、持续、难治性头痛和偏头痛表型患者的依那度胺持续使用 2 年的真实世界数据和生活质量数据：大多数病例为新的每日持续性头痛或持续性创伤后头痛。
Cephalalgia. 2023 Jun;43(6):3331024231182126. doi: 10.1177/03331024231182126.
5
Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.依瑞奈尤单抗治疗重度治疗抵抗性偏头痛患者：首个德国真实世界证据。
J Headache Pain. 2020 Jul 3;21(1):84. doi: 10.1186/s10194-020-01151-0.
6
The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study.抗 CGRP 单克隆抗体对耐药性偏头痛患者的影响：真实世界证据观察性研究。
J Neurol. 2021 Oct;268(10):3789-3798. doi: 10.1007/s00415-021-10523-8. Epub 2021 Mar 27.
7
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany.偏头痛预防中单克隆抗体依瑞奈umab 的真实世界证据数据：德国治疗医生的观点。
J Headache Pain. 2021 Nov 6;22(1):133. doi: 10.1186/s10194-021-01344-1.
8
Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months.177 例治疗抵抗或治疗困难的慢性偏头痛患者接受依那西普治疗的中期真实世界数据：17-30 个月后的持久性和患者报告结局测量。
J Headache Pain. 2023 Jan 16;24(1):5. doi: 10.1186/s10194-022-01536-3.
9
Preventive Migraine Treatment.预防性偏头痛治疗。
Continuum (Minneap Minn). 2021 Jun 1;27(3):613-632. doi: 10.1212/CON.0000000000000957.
10
A real-world, observational study of erenumab for migraine prevention in Canadian patients.在加拿大患者中进行的依瑞奈umab 预防偏头痛的真实世界、观察性研究。
Headache. 2022 Apr;62(4):522-529. doi: 10.1111/head.14291. Epub 2022 Apr 10.
本文引用的文献
1
Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis.治疗抵抗性慢性偏头痛中从抗 CGRP 受体抗体转换为抗 CGRP 配体抗体的长期疗效：一项前瞻性真实世界分析。
Neurotherapeutics. 2023 Sep;20(5):1284-1293. doi: 10.1007/s13311-023-01394-0. Epub 2023 Jul 10.
2
The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis.偏头痛预防药物的疗效比较：系统评价和网络荟萃分析。
J Headache Pain. 2023 May 19;24(1):56. doi: 10.1186/s10194-023-01594-1.
3
Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.依替巴肽治疗偏头痛预防失败患者的疗效和安全性：随机、安慰剂对照 DELIVER 研究的亚组分析。
Cephalalgia. 2023 May;43(5):3331024231170807. doi: 10.1177/03331024231170807.
4
New Approaches to Shifting the Migraine Treatment Paradigm.转变偏头痛治疗模式的新方法。
Front Pain Res (Lausanne). 2022 Sep 6;3:873179. doi: 10.3389/fpain.2022.873179. eCollection 2022.
5
Central Sensitization in Migraine: A Narrative Review.偏头痛中的中枢敏化：一篇叙述性综述。
J Pain Res. 2022 Sep 7;15:2673-2682. doi: 10.2147/JPR.S329280. eCollection 2022.
6
Applying a biopsychosocial model to migraine: rationale and clinical implications.应用生物心理社会模式于偏头痛：原理与临床意义。
J Headache Pain. 2022 Aug 11;23(1):100. doi: 10.1186/s10194-022-01471-3.
7
Therapies targeting CGRP signaling for medication overuse headache.针对药物过度使用性头痛的 CGRP 信号靶向治疗。
Curr Opin Neurol. 2022 Jun 1;35(3):353-359. doi: 10.1097/WCO.0000000000001061.
8
Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.偏头痛对降钙素基因相关肽受体抗体治疗无应答者抗体转换的影响：一项多中心回顾性队列研究。
Cephalalgia. 2022 Apr;42(4-5):291-301. doi: 10.1177/03331024211048765. Epub 2021 Oct 13.
9
Early Experiences in Switching between Monoclonal Antibodies in Patients with Nonresponsive Migraine in Spain: A Case Series.西班牙非应答型偏头痛患者在单抗药物间转换的早期经验：一项病例系列研究。
Eur Neurol. 2022;85(2):132-135. doi: 10.1159/000518899. Epub 2021 Sep 10.
10
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance.抗药性和难治性偏头痛的负担与态度：一项由欧洲头痛联盟认可、欧洲偏头痛与头痛联盟发起的调查
J Headache Pain. 2021 May 18;22(1):39. doi: 10.1186/s10194-021-01252-4.
Zotero 插件